STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1809 by analyst upside · 2026-08-12
CLDX
Celldex Therapeutics, Inc.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+31.0%
implied upside to consensus target
Current Price $44.33
Consensus Target $58.07
Bull Target $100.0
Bear Target $38.0
Analysts Covering 15
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
12
Hold
1
Sell
0
52-Week Low $20.19
52-Week High $44.59
YTD Return +64.1%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-4.35
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $20.19
52-Week High $44.59
Current Price $44.33
Bear Target $38.0
Bull Target $100.0
● Now $44.33 ● Target $58.07
TRADING DATA
Avg Volume 1.0M
YTD Return +64.1%
Analyst Count 15
Consensus Buy
Upside to Target +31.0%
Last Updated 2026-08-12

ANALYST SUMMARY

Celldex Therapeutics, Inc. (CLDX) is currently trading at $44.33 with a Wall Street consensus price target of $58.07, implying potential upside of 31.0% over the next 12 months. 15 analysts currently cover CLDX, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $100.0, while the most cautious has a target of $38.0.

CLDX operates in the Healthcare sector with a market capitalisation of $3B. The stock is up 64.1% year-to-date and is currently trading near the upper end of its 52-week range of $20.19 – $44.59.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CLDX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-06-15 31% win rate (48 calls)
UBS - Reiterated
Buy → Buy 2026-06-10 33% win rate (6 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-05-13 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-05-08 Building track record
Barclays ↑ Upgrade
Underweight → Overweight 2026-04-20 Building track record
Goldman Sachs - Reiterated
Neutral → Neutral 2026-03-02 Building track record
Stifel reit
Buy → Buy 2026-02-26 Building track record
Barclays - Reiterated
Underweight → Underweight 2025-12-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
21/30
Consensus clarity
2/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →